NASDAQ
Argenx discontinues its Phase 3 UplighTED trial in thyroid eye disease after an interim futility review, while analysts maintain confidence in Vyvgart's broader growth....
Corient Private Wealth LLC reduced its stake in Amgen Inc. (NASDAQ: AMGN) by 2.2% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commiss...
Caldwell Trust Co acquired a new stake in shares of Amgen Inc. (NASDAQ: AMGN) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC...
These two pharmaceutical giants have faced -- or will soon face -- patent cliffs. Both are innovative drugmakers, which should allow them to overcome this issue....
The rapid rise of artificial intelligence (AI) has transformed the stock market in recent years, powering massive gains in technology giants and growth-oriented investments. At the same time, dividend...
New York, Dec. 12, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) recognizes the U.S. Food and Drug Administration (FDA) approval of Amgen's UPLIZNA® (inebilizumab-cdon) for the tre...
AMGN gains momentum as Uplizna wins FDA approval for generalized myasthenia gravis, adding a twice-yearly dosing option in a crowded autoimmune market....
UPLIZNA Offers gMG Patients Deep and Durable Symptom Control and Twice-Yearly Dosing* First and Only CD19-Targeted B Cell Therapy Approved in anti-AChR and anti-MuSK Ab+ gMG THOUSAND OAKS, Calif. , De...
THOUSAND OAKS, Calif. , Dec. 9, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.52 per share dividend for the first quarter of 2026....
I see a generational opportunity in quality stocks, defined by high ROE, stable earnings growth, and low debt. Quality stocks have underperformed AI-driven leaders, creating rare relative value and at...
No price data available for this timeframe.